Overview
Brown-Vialetto-van Laere Syndrome (BVVLS) is an extremely rare, progressive neurological disorder characterized by sensorineural hearing loss and a range of motor and sensory deficits. It is also known as riboflavin transporter deficiency, as it is often linked to mutations in the SLC52A2 or SLC52A3 genes, which are responsible for the transport of riboflavin (vitamin B2) within the body. The syndrome typically presents in childhood or early adulthood, though onset can vary.
Symptoms and Progression
The hallmark initial symptom is often bilateral sensorineural hearing loss, which can progress to profound deafness. Other common symptoms include:
- Bulbar palsy (difficulty with swallowing, speaking, and drooling)
- Progressive muscle weakness (especially in the limbs and face)
- Respiratory difficulties due to muscle weakness
- Optic atrophy and vision loss
- Sensory ataxia and loss of balance
- Fatigue and feeding difficulties
The progression of the disease varies, but without intervention, it can lead to severe disability and respiratory failure.
Causes
BVVLS is primarily caused by mutations in the SLC52A2 or SLC52A3 genes. These genes encode riboflavin transporters, which are essential for the absorption and distribution of vitamin B2. Riboflavin is crucial for energy metabolism and the maintenance of nervous system function. The deficiency leads to impaired cellular energy production and neurodegeneration.
Diagnosis
Diagnosis is based on clinical presentation, hearing tests, nerve conduction studies, and genetic testing to identify mutations in the SLC52A2 or SLC52A3 genes. Blood tests may show low riboflavin levels, but genetic confirmation is the gold standard.
Treatment and Management
Treatment primarily involves high-dose oral riboflavin (vitamin B2) supplementation, which has been shown to halt or even reverse some symptoms in a subset of patients, particularly when started early. Other management strategies include:
- Speech and physical therapy
- Hearing aids or cochlear implants for hearing loss
- Respiratory support (e.g., non-invasive ventilation)
- Nutritional support via feeding tubes if swallowing is impaired
- Regular monitoring by a multidisciplinary team
Prognosis varies, but early diagnosis and riboflavin therapy can significantly improve outcomes and quality of life.
Research and Outlook
Ongoing research continues to explore the mechanisms of riboflavin transporter deficiency and potential new therapies. While BVVLS remains a rare and often devastating condition, increased awareness and genetic testing have improved early detection and intervention. Patient registries and advocacy groups play a vital role in supporting families and advancing research.